Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT
Authors' conclusion
Rivaroxaban demonstrated similar efficacy to warfarin in treating post-MI LVT, with >95% resolution in both groups. Future multicenter trials with longer follow-up are needed to validate these findings (Rivaroxaban in Left Ventricular Thrombus; NCT04970576).
Study context
- Population
- Patients with acute left ventricular thrombus (LVT) diagnosed during initial MI hospitalizationrandomized
- Participants
- 261 patients
- Comparison
- Rivaroxaban vs warfarin in treating post-myocardial infarction acute LVT
- Rivaroxabann = 171
- Warfarinn = 90
- Primary endpoint
- LVT resolution, assessed by echocardiography
- Follow-up
- 4 and 12 weeks
Primary result
As reported in the abstract
4 weeks
12 weeks
Further findings
Cumulative all-cause mortality
- Cumulative all-cause mortality: P = 0.921
Safety
Major bleeding
- Major bleeding: P = 0.491
Original publication
Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT. JACC Adv. Published 23 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it